< Back to previous page
Researcher
Eric Van Cutsem
- Disciplines:Oncology
Affiliations
- Digestive Oncology (Division)
Member
From1 Aug 2022 → Today - Clinical Digestive Oncology (Division)
Member
From1 Jan 2012 → 31 Jul 2022 - Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → 31 Dec 2011
Projects
11 - 13 of 13
- A phase I dose-escalation study to determine the maximum tolerated dose of radiotherapy, in combination with concomitant 5-FU chemptherapy, in patients with locally advanced rectal cancer with a positive circumferential resection margin (cCRM).From1 Jan 2009 → 31 Dec 2010Funding: Private funding of national origin - undefined
- Evaluation of molecular, dosimetric and ultrastructural imaging in the management of neuroendocrine tumors with Peptide Receptor Radionuclide Therapy: results of a prospective, monocentric, non-controlled phase II studyFrom1 Nov 2008 → 27 May 2015Funding: Nonprofit institution or equivalents
- Outcome after minimally invasive vs. open resection of liver metastases from colorectal cancer; rondomized controlled trialFrom1 Sep 2008 → 20 Sep 2009Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 10 of 726
- Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer(2023)
Authors: Eric Van Cutsem
- The ongoing search for biomarkers of response to systemic therapy in advanced hepatocellular carcinoma.(2023)
Authors: Sarah Cappuyns, Jeroen Dekervel, Eric Van Cutsem, Chris Verslype, Diether Lambrechts
- Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial(2023)
Authors: Eric Van Cutsem
- Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164.(2023)
Authors: Eric Van Cutsem
Pages: 185 - 195 - Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.(2023)
Authors: Eric Van Cutsem
Pages: 1655 - 1668 - ANCHOR CRC: Results From a Single-Arm , Phase II Study of Encorafenib Plus Binimetinib and Cetuximab in Previously Untreated BRAFV600E-Mutant Metastatic Colorectal Cancer(2023)
Authors: Eric Van Cutsem, Jeroen Dekervel
Pages: 2628 - + - Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer(2023)
Authors: Eric Van Cutsem
Pages: 1657 - 1667 - Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.(2023)
Authors: Eric Van Cutsem
Pages: 496 - 508 - Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study(2023)
Authors: Eric Van Cutsem
Pages: 483 - 495 - A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive system(2023)
Authors: Annemarie Coolbrandt, Annouschka Laenen, Hans Wildiers, Chris Verslype, Jeroen Dekervel, Eric Van Cutsem